On November 18, 2024 OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, reported participation in the 2024 Georgia Bio Life Sciences Summit last month from October 21 to October 22, 2024, where the company was featured in the prestigious Company Showcase (Press release, OncoSpherix, NOV 18, 2024, View Source [SID1234648473]). This event provided a valuable platform for OncoSpherix to present its pioneering developments in cancer therapies and underscore its commitment to advancing cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Georgia Bio Life Sciences Summit, known for bringing together key players in the biotechnology and life sciences sectors, offered OncoSpherix an opportunity to engage with industry leaders, investors, and researchers. The Company Showcase spotlighted OncoSpherix’s unique approach to precision oncology, focusing on therapies designed to block activation of HIF and combat hard-to-treat cancers more effectively.

"We are honored to have been part of the Company Showcase at the 2024 Georgia Bio Life Sciences Summit," said OncoSpherix CEO, Margaret Offermann, MD, PhD. "This platform allowed us to share our breakthroughs in developing new drugs for oncology and our mission to bring innovative, effective therapies to patients in need. The positive response from the community reinforces our commitment to developing solutions that will make a significant impact on cancer treatment."